Monte Rosa Therapeutics, Inc. (GLUE)

Income Statement (Trailing)

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Quarter Ending	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31
Selling, General & Admin	19.88	15.73	12.54	8.7	5.76	4.01	-	-	-	0.64
Research & Development	65.8	57.16	48.89	39.25	29.46	24.01	-	-	-	7.35
Operating Expenses	85.68	72.88	61.43	47.95	35.22	28.01	-	-	-	7.99
Operating Income	-85.68	-72.88	-61.43	-47.95	-35.22	-28.01	-	-	-	-7.99
Interest Expense / Income	0	0	0	0	0	0	-	-	-	-0
Other Expense / Income	-0.07	1.08	8.74	8.95	8.63	7.87	0	0	0	-0.25
Pretax Income	-85.61	-73.96	-70.17	-56.9	-43.85	-35.88	0	0	0	-7.74
Net Income	-85.61	-73.96	-70.17	-56.9	-43.85	-35.88	-	-	-	-7.74
Net Income Common	-85.61	-73.96	-70.17	-56.9	-43.85	-35.88	-	-	-	-7.74
Shares Outstanding (Basic)	47	25	46	5	2	2	2	1	1	5
Shares Outstanding (Diluted)	47	25	46	5	2	2	-	-	-	5
Shares Change	2626.13%	1548.09%	-	-	-	-69.66%	-	-	-	-
EPS (Basic)	-4.68	-2.96	-23.88	-27.74	-27.75	-23.65	-	-	-	-1.55
EPS (Diluted)	-4.68	-2.96	-23.88	-27.74	-27.75	-23.65	-	-	-	-1.55
Free Cash Flow Per Share	-1.76	-2.76	-1.34	-9.84	-22.87	-17.43	-	-	-	-1.51
EBITDA	-82.62	-71.83	-68.63	-55.76	-43.11	-35.34	-	-	-	-7.67
Depreciation & Amortization	2.99	2.13	1.55	1.14	0.74	0.54	-	-	-	0.07
EBIT	-85.61	-73.96	-70.17	-56.9	-43.85	-35.88	-	-	-	-7.74

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).